Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis

NCT06652464 | Completed

• 1 other identifier: 2024 - 01/07
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Specialized pro-resolving mediators (SPMs), which are typically thought to be formed via consecutive steps of oxidation of polyenoic fatty acids, have been shown to suppress inflammation and promote timely resolution of inflammation. They are mainly divided into four categories: lipoxins, resolvins, protectins, and maresins. The study will compare Maresin-1 and Resolvin-D1 levels in ulcerative colitis patients with those in the control group.

Conditions

Disease Activity; Remission of Ulcerative Colitis; Ulcerative Colitis Flare

Keywords

maresin-1; resolvin-D1; ulcerative colitis

Outcome Measures

Primary Outcomes (1)

• İnflammatory markers

  Maresin-1 and Resolvin-D1 levels in study groups

  Up to 2 months

Secondary Outcomes (1)

• İnflammatory markers

  Up to 2 months

Study Arms (3)

Active

Group of ulcerative colitis patients considered active according to the Mayo score. (30 patients)

Remission

Group of ulcerative colitis patients considered remission according to the Mayo score. (30 patients)

Control

Group without ulcerative colitis or inflammatory disease. (30 patients)

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with active and remission phase ulcerative colitis and those in the control group who presented to the gastroenterology outpatient clinic of our hospital.

You may qualify if:

• Patients with ulcerative colitis in active and remission phases, and a control group without acute or chronic inflammatory disease.

You may not qualify if:

• Active malignancy
• Chronic kidney disease
• Diabetes mellitus
• Collagen tissue disease
• History of colectomy
• Acute infection
• Pregnancy / lactation period
• Within the past week, history of omega-3 dietary supplementation, non-steroidal anti-inflammatory drug use, or fish consumption.

Sponsors & Collaborators

• Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital: lead

Study Sites (1)

Abdurrahman Yurtaslan Oncology and Training Research Hospital

Ankara, 06200, Turkey (Türkiye)

Location

Related Publications (3)

• Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005 Dec;6(12):1191-7. doi: 10.1038/ni1276.

  PMID: 16369558 BACKGROUND

• Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014 Mar 20;40(3):315-27. doi: 10.1016/j.immuni.2014.02.009.

  PMID: 24656045 BACKGROUND

• Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009 Jan 16;206(1):15-23. doi: 10.1084/jem.20081880. Epub 2008 Dec 22.

  PMID: 19103881 BACKGROUND

MeSH Terms

Conditions

Colitis, Ulcerative

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Study Officials

• selim demirci, medical doctor

  Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 15, 2024
• First Posted: October 22, 2024
• Study Start: August 1, 2024
• Primary Completion: November 1, 2024
• Study Completion: November 15, 2024
• Last Updated: March 7, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)